In a groundbreaking discovery, scientists have uncovered a surprising link between COVID-19 infection and cancer regression, where tumors significantly reduce in size or severity. Researchers from Illinois observed that RNA molecules from the SARS-CoV-2 virus, which causes COVID-19, stimulate the formation of a unique immune cell with anti-cancer properties.
These cells, known as inducible nonclassical monocytes (I-NCMs), specifically target cancer cells and could potentially offer a new avenue for treating cancers resistant to current therapies.
As reported by timesnownews, the research, conducted by Northwestern Medicine’s Canning Thoracic Institute, holds promising implications for cancer treatment. “This discovery opens up a new pathway for cancer therapy,” said Dr. Ankit Bharat, Chief of Thoracic Surgery at the institute. “We found that the same cells activated during severe COVID-19 could be induced with a drug to combat cancer. Notably, our study demonstrated responses in melanoma, lung, breast, and colon cancers,” he added.
Effectiveness Currently Limited to Animal Models
The study remains in its early stages, with demonstrated effectiveness only in animal models thus far. However, Dr. Bharat expressed optimism, stating, “This research offers hope for benefiting patients with advanced cancers that have not responded to other treatments.”
The team suggests that these unique immune cells could be enhanced using small molecules, paving the way for innovative therapies for cancer patients who have exhausted traditional options.
How I-NCMs Combat Cancer
What sets I-NCMs apart is their dual functionality. Typically, non-classical monocytes patrol blood vessels to detect threats but are unable to penetrate tumors due to the lack of specific receptors. During severe COVID-19, these cells gain a unique receptor called CCR2, enabling them to infiltrate tumor environments.
Once inside the tumor, these cells release chemicals that attract the body’s natural killer cells. Together, they attack and shrink the tumor.
Future Research and Clinical Trials
While the findings are promising, further research is required before they can be applied in clinical settings. According to Dr. Bharat, clinical trials are the next step, but practical applications are still years away.
Cancer Statistics
Cancer, characterized by uncontrolled cell growth and spread, varies in survivability depending on the type. In 2024, an estimated 611,720 individuals in the U.S. are expected to succumb to the disease, with lung cancer accounting for a significant proportion of these deaths.
This discovery offers a glimmer of hope for reimagining cancer treatment and highlights the potential of leveraging unexpected biological mechanisms for therapeutic innovation.